Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

HDAC Activity in Peripheral Skeletal Muscle in COPD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Polkey, Imperial College London
ClinicalTrials.gov Identifier:
NCT00180752
First received: September 13, 2005
Last updated: February 17, 2016
Last verified: August 2008
  Purpose
We wish to study the effect of Chronic Obstructive Pulmonary Disease on the activity of the nuclear transcription pathway in peripheral skeletal muscle to determine whether altered activity of this pathway may be responsible for the muscle dysfunction observed in these patients.

Condition
COPD

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Investigation of HDAC and NF Kappa B Activity in Peripheral Skeletal Muscle in COPD

Further study details as provided by Imperial College London:

Biospecimen Retention:   Samples With DNA
Plasma and serum samples, quadriceps muscle specimens

Enrollment: 31
Study Start Date: September 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Detailed Description:
Peripheral muscle dysfunction is well recognised in COPD. We wish to study patients who we have found to have weak quadriceps muscles and study the molecular mechanisms underlying this problem. Patients will be well characterised with regard to their physiologic parameters and quadriceps muscle biopsies will be taken. These biopsy samples will be analysed with respect to NFkappaB activity and HDAC activity by nuclear extraction and for muscle inflammatory cytokines. We know that in the lung tissue of COPD patients there is evidence of a reduction in HDAC activity which might be responsible for the higher levels of pronflammatory cytokines in the lung. We will also study a healthy control group and a small selection of patients who are in respiratory failure due to idiopathic scoliosis in the same way.
  Eligibility

Ages Eligible for Study:   40 Years to 85 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
COPD patients and healthy age-and sex-matched controls
Criteria

Inclusion Criteria:

COPD

Exclusion Criteria:

Aspirin therapy Bleeding diasthesis Neuromuscular disease

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180752

Locations
United Kingdom
Royal Brompton Hospital
London, United Kingdom, SW3 6NP
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Michael I Polkey, PhD Royal Brompton & Harefield NHS Foundation Trust
  More Information

Publications:
Responsible Party: Michael Polkey, Professor of Respiratory Medicine, Imperial College London
ClinicalTrials.gov Identifier: NCT00180752     History of Changes
Other Study ID Numbers: MusHDAC -1 
Study First Received: September 13, 2005
Last Updated: February 17, 2016
Health Authority: United Kingdom: Research Ethics Committee
Individual Participant Data  
Plan to Share IPD: No

ClinicalTrials.gov processed this record on December 08, 2016